Invention Grant
- Patent Title: CD47-CAR-T cells
-
Application No.: US16521421Application Date: 2019-07-24
-
Publication No.: US11692034B2Publication Date: 2023-07-04
- Inventor: Lijun Wu , Vita Golubovskaya
- Applicant: ProMab Biotechnologies, Inc. , Forevertek Biotechnology Co., Ltd
- Applicant Address: US CA Richmond
- Assignee: ProMab Biotechnologies, Inc.,Forevertek Biotechnology Co., Ltd
- Current Assignee: ProMab Biotechnologies, Inc.,Forevertek Biotechnology Co., Ltd
- Current Assignee Address: US CA Richmond; CN Changsha
- Agency: Perkins Coie LLP
- Agent Viola Kung
- Main IPC: C07K14/705
- IPC: C07K14/705 ; C07K14/71 ; C07K14/725 ; C07K16/28 ; C12N5/0783
Abstract:
The present invention provides a chimeric antigen receptor (CAR) fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) comprising VH and VL, wherein scFv has an activity against CD47, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. In one embodiment, the scFv is derived from a humanized anti-CD47 antibody. The present invention also provides T cells modified to express the CAR of the present invention.
Public/Granted literature
- US20190338028A1 CD47-CAR-T CELLS Public/Granted day:2019-11-07
Information query
